What You Should Know:
- Syapse raises $35M led by an affiliate of Innovatus Capital Partners, LLC (Innovatus)to tackle the challenge of understanding, preventing, and treating complex cancers.
- The investment will allow Syapse to expand its artificial intelligence and machine learning capabilities, making it more efficient to uncover meaningful insights from real-world oncology data.
Syapse, a San Francisco, CA-based real-world evidence company accelerating the
Read More
Impact of Precision Medicine| News, Policy, Analysis, Insights - HIT Consultant
Mayo Clinic, Mercy Sign 10-Year Collaboration to Transform Patient Care
What You Should Know:
- Mayo Clinic and Mercy announced a 10-year collaboration agreement— a first-of-its-kind alliance between two large healthcare systems that will use the most current data science and years of deidentified patient outcomes to find diseases earlier and start patients on paths to better health more quickly.
- With the combination of privacy-protected, cloud-based technology architecture, and the growth of artificial intelligence and machine learning, this aggregated
Read More
Epic Integrates Caris Molecular Testing Portfolio with Epic’s ORA Network
What You Should Know:
- Caris Life Sciences (Caris), the leading molecular science and technology company today announced an enhanced partnership with Epic to integrate Caris' market-leading molecular testing portfolio with Epic's Orders and Results Anywhere (ORA) network.
- Caris builds upon its current Genomics Module integration within the nation's largest electronic health record provider by offering seamless ordering and receipt of Caris molecular profiling results directly in patient
Read More
Precision Medicine: Is Personalized Care Really Here?
What You Should Know:
- New Definitive Healthcare report, Is Personalized Care Really Here? analyzes the US claims data to review how precision medicine has been used in recent years for cancer, transplant matching, genetic testing during pregnancy and more.
- Trends within — and adjacent to — precision medicine suggests that consumer preferences for more effective, convenient and affordable care are driving rising rates of precision medicine procedures. Furthermore, the data reveal the
Read More
Proscia Raises $37M for AI-Enabled Pathology Platform
What You Should Know:
- Proscia, a Philadelphia-based provider of digital and computational pathology solutions raises $37M to advance the way we understand and treat diseases like cancer. The round includes participation from Highline Capital Management, Triangle Peak Partners, and Alpha Intelligence Capital as well as existing investors including Scale Venture Partners, Hitachi Ventures, ROBO Global, Emerald Development Managers, and Razor's Edge Ventures. This investment brings Proscia's
Read More
Syapse and Pierian Partner to Power Precision Oncology
What You Should Know:
- Syapse, a real-world evidence company is teaming up with Pierian®, a provider of advanced clinical genomics technology on a new joint collaboration that will benefit patients of the AdventHealth Cancer Institute in Central Florida.
- The collaboration combines Syapse’s real-world evidence solutions designed to improve outcomes for patients with cancer, Pierian’s leading-edge clinical genomics workflow, and precision medicine services that provide the most relevant
Read More
L7 Informatics Raises $38M to Digitalize Precision Healthcare
What You Should Know:
- L7 Informatics, a leader in software for life sciences that delivers a flexible end-to-end platform for precision healthcare, today announced a $38M investment led by Banneker Partners with participation from its pre-existing investors.
- The company will use the new funding to accelerate product development, expand L7|ESP's global reach, and build on L7's outstanding customer support.
Precision healthcare offers significant improvements in
Read More
Geisinger & Tempus Create AI Model to Identify Structural Heart Disease
What You Should Know:
- Tempus, an $8B precision medicine company, announced a collaborative study with Geisinger focusing on artificial intelligence (AI) model that can accurately identify patients at increased risk of undiagnosed structural heart disease (SHD). The study addresses a critical diagnostic gap – SHD is a progressive disease that affects the valves, walls, chambers, and muscles of the heart, and causes debilitating symptoms or death, yet many patients with the disease go
Read More
BestLife Holdings Raises $50M+ Portfolio Expansion with Cenegenics
What You Should Know:
- BestLife Holdings, a portfolio of personalized preventative healthcare and age management solutions, announces its formation with a combined equity round of over $50M. Notable investors have partnered with BestLife including PrimeTime Partners’ founders, Abby Levy, the co-founder of Thrive Global with Arianna Huffington, and Alan Patricof, founder of Greycroft Partners and Apax Partners, who also joined the board as an observer. Consumer and digital health
Read More
Tempus Launches Psychiatric Real-World Data Collaboration
What You Should Know:
- Tempus, an $8B precision medicine company, announced the launch of a new psychiatric real-world data program to leverage real-world data to inform mental health treatment.
- Tempus N+ is a collaboration between provider institutions across the country and Tempus to build an infrastructure for data-driven research – providers can seamlessly and securely contribute molecular and clinical data, and in turn, their clinicians and researchers can access a
Read More
